Neel Named Director of NYU’s Perlmutter Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BENJAMIN NEEL was named director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center. He will begin Jan. 1, 2015.

Neel will oversee translational programs in immunotherapy, cancer genetics/targeted therapies and epigenetics, imaging, community outreach and supportive oncology. He will also be responsible for all programs throughout NYU Langone’s network of cancer-related clinical care.

Neel most recently served as director of the Ontario Cancer Institute at Princess Margaret Cancer Center. He also served as professor of medical biophysics at the University of Toronto, and holds a Tier 1 Canada Research Chair in signal transduction and disease. His research has focused on cell signaling in cancer and developmental disease, functional genomics of breast cancer and ovarian cancer tumor initiating cells.

He was appointed assistant professor of medicine at Harvard Medical School in 1988, and began his own independent research laboratory in the Molecular Medicine Unit at Beth Israel Hospital, now known as Beth Israel Deaconess Medical Center. He also served as the director of the Cancer Biology Program from 1994-2007 and as deputy director for basic research in the Hematology Division at BIDMC from 2003-2007. In 2006, he was appointed to the William B. Castle Chair of Medicine at Harvard Medical School.

He is also an elected member of the Board of Directors for the American Association for Cancer Research, and previously served as the program chair for the annual meeting of the AACR.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login